DA-7867

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581147

CAS#: 380382-38-7

Description: DA-7867 is a novel oxazolidinone. In vitro activities of DA-7867 were compared to those of linezolid and commonly used antimicrobials. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested,

Chemical Structure

img
DA-7867
CAS# 380382-38-7
Instruction

Theoretical Analysis

MedKoo Cat#: 581147
Name: DA-7867
CAS#: 380382-38-7
Chemical Formula: C19H18FN7O3
Exact Mass: 411.15
Molecular Weight: 411.400
Elemental Analysis: C, 55.47; H, 4.41; F, 4.62; N, 23.83; O, 11.67

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: DA-7867; DA 7867; DA7867; UNII-491MT9GU8K;

IUPAC/Chemical Name: Acetamide, N-(((5S)-3-(3-fluoro-4-(6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-

InChi Key: XLLXHGCGAQJLLK-AWEZNQCLSA-N

InChi Code: InChI=1S/C19H18FN7O3/c1-11(28)21-9-14-10-27(19(29)30-14)13-4-5-15(16(20)7-13)12-3-6-17(22-8-12)18-23-24-25-26(18)2/h3-8,14H,9-10H2,1-2H3,(H,21,28)/t14-/m0/s1

SMILES Code: CC(NC[C@H]1CN(C2=CC=C(C3=CC=C(C4=NN=NN4C)N=C3)C(F)=C2)C(O1)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 411.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Vera-Cabrera L, Castro-Garza J, Rendon A, Ocampo-Candiani J, Welsh O, Choi SH, Blackwood K, Molina-Torres C. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob Agents Chemother. 2005 Oct;49(10):4351-3. PubMed PMID: 16189119; PubMed Central PMCID: PMC1251498.

2: Yong D, Yum JH, Lee K, Chong Y, Choi SH, Rhee JK. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2004 Jan;48(1):352-7. Erratum in: Antimicrob Agents Chemother. 2004 May;48(5):1918. PubMed PMID: 14693566; PubMed Central PMCID: PMC310204.

3: Vera-Cabrera L, Brown-Elliott BA, Wallace RJ Jr, Ocampo-Candiani J, Welsh O, Choi SH, Molina-Torres CA. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria. Antimicrob Agents Chemother. 2006 Dec;50(12):4027-9. Epub 2006 Oct 2. PubMed PMID: 17015632; PubMed Central PMCID: PMC1693997.

4: Vera-Cabrera L, Daw-Garza A, Said-Fernández S, Lozano-Garza HG, de Torres NW, Rocha NC, Ocampo-Candiani J, Choi SH, Welsh O. Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis. PLoS Negl Trop Dis. 2008 Sep 10;2(9):e289. doi: 10.1371/journal.pntd.0000289. PubMed PMID: 18820738; PubMed Central PMCID: PMC2553479.

5: Yoon EJ, Jo YW, Choi SH, Lee TH, Rhee JK, Yoo M, Shim MJ, Choi EC. In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria. Antimicrob Agents Chemother. 2005 Jun;49(6):2498-500. PubMed PMID: 15917554; PubMed Central PMCID: PMC1140508.

6: Ji HY, Lee HW, Chang SG, Lee JJ, Rhee JK, Kim WB, Lee HS. Liquid chromatography-tandem mass spectrometry for the determination of a new oxazolidinone antibiotic DA-7867 in human plasma. Biomed Chromatogr. 2004 Mar;18(2):86-9. PubMed PMID: 15039959.

7: Bae SK, Kwon JW, Kim WB, Lee I, Lee MG. Effects of acute renal failure on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. Biopharm Drug Dispos. 2006 Jan;27(1):29-37. PubMed PMID: 16302289.

8: Bae SK, Lee SJ, Kwon JW, Kim WB, Lee MG. Effects of protein-calorie malnutrition on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. J Pharm Pharmacol. 2004 May;56(5):635-42. PubMed PMID: 15142341.

9: Bae SK, Chung WS, Kim EJ, Rhee JK, Kwon JW, Kim WB, Lee MG. Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone. Biopharm Drug Dispos. 2004 Apr;25(3):127-35. PubMed PMID: 15083501.

10: Bae SK, Kim YC, Lee JK, Kwon JW, Yoo M, Lee I, Lee MG. Effects of water deprivation for 72 hours on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. Biopharm Drug Dispos. 2006 Apr;27(3):147-56. PubMed PMID: 16408258.

11: Bae SK, Yang SH, Lee SJ, Kwon JW, Kim WB, Lee DC, Lee MG. Pharmacokinetic changes of DA-7867, a new oxazolidinone, after intravenous and oral administration to rats with short-term and long-term diabetes mellitus induced by streptozotocin. Eur J Pharm Sci. 2005 Jun;25(2-3):337-45. Epub 2005 Apr 22. PubMed PMID: 15911231.

12: Bae SK, Chung WS, Kim EJ, Rhee JK, Kwon JW, Kim WB, Lee MG. Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother. 2004 Feb;48(2):659-62. PubMed PMID: 14742232; PubMed Central PMCID: PMC321507.

13: Bae SK, Kim EJ, Kwon JW, Kim WB, Lee MG. High-performance liquid chromatographic analysis of DA-7867, a new oxazolidinone, in human plasma and urine and in rat tissue homogenates. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 5;794(2):397-403. PubMed PMID: 12954392.

14: Bae SK, Kim EJ, Kwon JW, Kim WB, Lee I, Lee MG. Excretion and metabolism of DA-7867, a new oxazolidinone, in rats. Biopharm Drug Dispos. 2005 Mar;26(2):67-75. PubMed PMID: 15617136.

15: Bae SK, Lee SJ, Kwon JW, Kim WB, Lee I, Lee MG. Effects of bacterial lipopolysaccharide on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. J Pharm Sci. 2004 Sep;93(9):2364-73. PubMed PMID: 15295796.

16: Vera-Cabrera L, Ochoa-Felix EY, Gonzalez G, Tijerina R, Choi SH, Welsh O. In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae. Antimicrob Agents Chemother. 2004 Mar;48(3):1037-9. PubMed PMID: 14982804; PubMed Central PMCID: PMC353109.

17: Vera-Cabrera L, Gonzalez E, Choi SH, Welsh O. In vitro activities of new antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother. 2004 Feb;48(2):602-4. PubMed PMID: 14742215; PubMed Central PMCID: PMC321515.

18: Sood R, Bhadauriya T, Rao M, Gautam R, Malhotra S, Barman TK, Upadhyay DJ, Rattan A. Antimycobacterial activities of oxazolidinones: a review. Infect Disord Drug Targets. 2006 Dec;6(4):343-54. Review. PubMed PMID: 17168800.